| Literature DB >> 26575856 |
Junsheng Ma1, Francesco C Stingo1, Brian P Hobbs1.
Abstract
Efforts to personalize medicine in oncology have been limited by reductive characterizations of the intrinsically complex underlying biological phenomena. Future advances in personalized medicine will rely on molecular signatures that derive from synthesis of multifarious interdependent molecular quantities requiring robust quantitative methods. However, highly parameterized statistical models when applied in these settings often require a prohibitively large database and are sensitive to proper characterizations of the treatment-by-covariate interactions, which in practice are difficult to specify and may be limited by generalized linear models. In this article, we present a Bayesian predictive framework that enables the integration of a high-dimensional set of genomic features with clinical responses and treatment histories of historical patients, providing a probabilistic basis for using the clinical and molecular information to personalize therapy for future patients. Our work represents one of the first attempts to define personalized treatment assignment rules based on large-scale genomic data. We use actual gene expression data acquired from The Cancer Genome Atlas in the settings of leukemia and glioma to explore the statistical properties of our proposed Bayesian approach for personalizing treatment selection. The method is shown to yield considerable improvements in predictive accuracy when compared to penalized regression approaches.Entities:
Keywords: Bayesian analysis; Genomics; Partial exchangeability; Personalized medicine; Predictive probability; Unsupervised clustering
Mesh:
Year: 2015 PMID: 26575856 PMCID: PMC4870163 DOI: 10.1111/biom.12448
Source DB: PubMed Journal: Biometrics ISSN: 0006-341X Impact factor: 2.571